Table 2 Clinical manifestation of patients who reached to end–stage renal disease
From: Long-term prognosis of clinically early IgA nephropathy is not always favorable
Patient A | Patient B | Patient C | Patient D | Patient E | Patient F | |
|---|---|---|---|---|---|---|
Body mass index (kg/m2) | 24.6 | Unknown | 18.3 | 21.6 | 23.2 | 21.4 |
Blood pressure (mmHg) | 110/10 | 130/90 | 100/70 | 110/70 | 110/70 | 100/60 |
Blood urea nitrogen (mg/dL) [10-26] | 9 | 17 | 12 | 12 | 12 | NA |
Serum creatinine (mg/dL) [0.70–1.40] | 1.00 | 1.20 | 0.90 | 1.20 | 0.70 | 1.30 |
Creatinine clearance (mL/min) | 78.5 | NA | 84 | 87 | NA | 66 |
eGFR (mL/min/1.73 m2) | 72.1 | 74.1 | 77.1 | 82.7 | 152.4 | 74.6 |
Serum albumin (g/dL) [3.3–5.2] | 4.6 | 4.9 | 3.5 | 4.4 | 4.0 | NA |
Proteinuria (g/day) | 0.21 | 0.22 | 0.35 | 0.34 | 0.18 | 0.20 |
WHO grade | III | II | II | III | III | NA |
Global sclerosis (N/Glom No) | 0/19 | 1/15 | 0/8 | 2/32 | 1/35 | 0/5 |
Segmental sclerosis (N/Glom No) | 0/19 | 0/15 | 0/8 | 2/32 | 2/35 | 0/5 |
Crescent formation (N/Glom No) | 0/19 | 0/15 | 0/8 | 0/32 | 0/35 | 0/5 |
Mesangial proliferation | None | Mild | None | Mild | Mild | Moderate |
Tubular atrophy | Mild | None | None | Moderate | Mild | NA |
Interstitial fibrosis | None | None | None | Mild | Mild | NA |
Interstitial inflammation | Mild | None | Mild | Moderate | None | NA |
Vascular change | None | None | None | None | None | None |
Time to ESRD (months) | 153 | 224 | 101 | 100 | 58 | 159 |